Though previous research on the matter has shown that the use of statins may help protect against Parkinson’s, Penn State researchers say that those results have been inconsistent. In the new study, researchers used insurance data to compare over 2000 patients with Parkinson’s to a control group of people who did not have the disease and found that those who took statins had a higher risk of developing Parkinson’s.
“Statin use was associated with higher, not lower, Parkinson’s disease risk, and the association was more noticeable for lipophilic statins, an observation inconsistent with the current hypothesis that these statins protect nerve cells,” said Xumei Huang, MD, a professor of neurology.
More Articles on Clinical Quality:
100 patient safety benchmarks | 2017
Tamiflu no longer a ‘core’ drug, per WHO update
Pediatric chemotherapy linked to cognitive issues later in life
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
